Shell Asset Management Co. raised its stake in Johnson & Johnson (NYSE:JNJ) by 1.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 489,384 shares of the company’s stock after acquiring an additional 4,883 shares during the period. Johnson & Johnson accounts for about 1.6% of Shell Asset Management Co.’s investment portfolio, making the stock its 3rd biggest holding. Shell Asset Management Co.’s holdings in Johnson & Johnson were worth $64,741,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Lenox Wealth Advisors Inc. boosted its stake in Johnson & Johnson by 0.6% in the second quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares during the period. Harel Insurance Investments & Financial Services Ltd. boosted its position in shares of Johnson & Johnson by 241.0% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock worth $149,000 after buying an additional 841 shares during the period. Ullmann Financial Group Inc. acquired a new position in shares of Johnson & Johnson during the first quarter worth approximately $186,000. Taylor Wealth Management Partners boosted its position in shares of Johnson & Johnson by 19.8% during the first quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after buying an additional 250 shares during the period. Finally, Puplava Financial Services Inc. acquired a new position in shares of Johnson & Johnson during the second quarter worth approximately $202,000. Institutional investors own 65.90% of the company’s stock.

JNJ has been the subject of several analyst reports. BidaskClub downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 1st. Morgan Stanley boosted their price objective on Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 5th. Wells Fargo & Company reiterated a “market perform” rating and set a $135.00 price objective (up from $132.00) on shares of Johnson & Johnson in a research report on Thursday, July 6th. Royal Bank Of Canada reiterated a “buy” rating and set a $138.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, July 12th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $145.00 price objective (up from $140.00) on shares of Johnson & Johnson in a research report on Friday, July 14th. Five analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $141.66.

COPYRIGHT VIOLATION NOTICE: “Shell Asset Management Co. Has $64.74 Million Holdings in Johnson & Johnson (JNJ)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/22/shell-asset-management-co-has-64-74-million-holdings-in-johnson-johnson-jnj.html.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.19% of the stock is currently owned by company insiders.

Johnson & Johnson (NYSE:JNJ) opened at 142.40 on Friday. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $143.62. The firm has a 50 day moving average price of $133.77 and a 200 day moving average price of $130.75. The company has a market cap of $382.20 billion, a PE ratio of 24.77 and a beta of 0.78.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.68%. The firm had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same period last year, the firm earned $1.68 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, analysts anticipate that Johnson & Johnson will post $7.27 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a $0.84 dividend. The ex-dividend date is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.36%. Johnson & Johnson’s payout ratio is presently 58.33%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.